6 [19] J. Byrne, T. R. Fears, J. L. Mills et al., “Fertility in women treated with cranial radiotherapy for childhood acute lym- phoblastic leukemia,” Pediatric Blood and Cancer, vol. 42, no. 7, pp. 589–597, 2004. [20] R. Nygaard, N. Clausen, M. A. Simes et al., “Reproduction following treatment for childhood leukaemia: a population- based prospective cohort study of fertility and oﬀspring,” Medical and Pediatric Oncology, vol. 19, no. 6, pp. 459–466, 1991. [21] L. E. Bath, R. A. Anderson, H. O. D. Critchley, C. J. H. Kelnar, and W. H. B. Wallace, “Hypothalamic-pituitary- ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia,” Human Reproduction, vol. 16, no. 9, pp. 1838–1844, 2001. [22] R. C. Reulen, M. P. Zeegers, W. H. B. Wallace et al., “Pregnancy outcomes among adult survivors of childhood cancer in the British childhood cancer survivor study,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 8, pp. 2239–2247, 2009. [23] D. M. Green, J. A. Whitton, M. Stovall et al., “Pregnancy outcome of female survivors of childhood cancer: a report from the childhood cancer survivor study,” American Journal of Obstetrics and Gynecology, vol. 187, no. 4, pp. 1070–1080, 2002. [24] J. F. Winther, J. D. Boice, A. L. Svendsen, K. Frederiksen, M. Stovall, and J. H. Olsen, “Spontaneous abortion in a Danish population-based cohort of childhood cancer survivors,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4340–4346, 2008. [25] D. M. Green, C. A. Sklar, J. D. Boice et al., “Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the childhood cancer survivor study,” Journal of Clinical Oncology, vol. 27, no. 14, pp. 2374–2381, 2009. [26] E. Block, “Quantitative morphological investigations of the follicular system in women; variations at diﬀerent ages,” Acta Anatomica, vol. 14, no. 1-2, pp. 108–123, 1952. [27] M. Faddy, R. Godsen, A. Gongeon, J. Richardson, and J. Nelson, “Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause,” Human Reproduction, vol. 7, no. 10, pp. 1342–1346, 1992. [28] R. J. Johnston and W. H. B. Wallace, “Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer,” Pediatric Blood and Cancer, vol. 53, no. 2, pp. 296–302, 2009. [29] S. J. Richardson, V. Senikas, and J. F. Nelson, “Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion,” Journal of Clinical Endocrinology and Metabolism, vol. 65, no. 6, pp. 1231–1237, 1987. [30] A. Treolar, “Menstrual cyclicity and the pre-menopause,” Maturitas, vol. 3, no. 3-4, pp. 249–264, 1981. [31] D. Meirow, “Reproduction post-chemotherapy in young can- cer patients,” Molecular and Cellular Endocrinology, vol. 169, no. 1-2, pp. 123–131, 2000. [32] D. M. Gershenson, “Menstrual and reproductive function after treatment with combination chemotherapy for malig- nant ovarian germ cell tumors,” Journal of Clinical Oncology, vol. 6, no. 2, pp. 270–275, 1988. [33] W. H. B. Wallace, A. B. Thomson, F. Saran, and T. W. Kelsey, “Predicting age of ovarian failure after radiation to a ﬁeld that includes the ovaries,” International Journal of Radiation Oncology Biology Physics, vol. 62, no. 3, pp. 738–744, 2005. [34] W. Chemaitilly, A. C. Mertens, P. Mitby et al., “Acute ovarian failure in the childhood cancer survivor study,” Journal of Obstetrics and Gynecology International Clinical Endocrinology and Metabolism, vol. 91, no. 5, pp. 1723–1728, 2006. [35] R. Stillman, J. Schinfeld, I. Schiﬀ et al., “Ovarian failure in long-term survivors of childhood malignancy,” American Journal of Obstetrics and Gynecology, vol. 139, pp. 62–66, 1981. [36] C. Sklar, “Maintenance of ovarian function and risk of premature menopause related to cancer treatment,” Journal of the National Cancer Institute. Monographs, no. 34, pp. 25–27, 2005. [37] C. A. Sklar, A. C. Mertens, P. Mitby et al., “Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study,” Journal of the National Cancer Institute, vol. 98, no. 13, pp. 890–896, 2006. [38] A. M. Chiarelli, L. D. Marrett, and G. Darlington, “Early menopause and infertility in females after treatment for child- hood cancer diagnosed in 1964–1988 in Ontario, Canada,” American Journal of Epidemiology, vol. 150, no. 3, pp. 245–254, 1999. [39] J. Byrne, T. R. Fears, M. H. Gail et al., “Early menopause in long-term survivors of cancer during adolescence,” American Journal of Obstetrics and Gynecology, vol. 166, no. 3, pp. 788– 793, 1992. [40] T. S. Domingues, A. M. Rocha, and P. C. Seraﬁni, “Tests for ovarian reserve: reliability and utility,” Current Opinion in Obstetrics and Gynecology, vol. 22, no. 4, pp. 271–276, 2010. [41] M. A. Rosencrantz, D. S. Wachs, M. S. Coﬄer, P. J. Malcom, M. Donohue, and R. J. Chang, “Comparison of inhibin B and estradiol responses to intravenous FSH in women with polycystic ovary syndrome and normal women,” Human Reproduction, vol. 25, no. 1, pp. 198–203, 2010. [42] A. de Vet, J. S. E. Laven, F. H. de Jong, A. P. N. Themmen, and B. C. J. M. Fauser, “Antim u¨llerian hormone serum levels: a putative marker for ovarian aging,” Fertility and Sterility, vol. 77, no. 2, pp. 357–362, 2002. [43] I. A. J. van Rooij, F. J. M. Broekmans, G. J. Scheﬀer et al., “Serum antim u¨llerian hormone levels best reﬂect the reproductive decline with age in normal women with proven fertility: a longitudinal study,” Fertility and Sterility, vol. 83, no. 4, pp. 979–987, 2005. [44] R. Hampl, A. Snajderova, and T. Mardesic, “Antim u¨llerian hormone (AMH) not only a marker for prediction of ovarian reserve,” Physiological Research, vol. 60, no. 2, pp. 271–223, 2011. [45] J. van Disseldorp, M. Faddy, A. Themmen et al., “Relation- ship of serum antim u¨llerian hormone concentration to age at menopause,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 6, pp. 2129–2134, 2008. [46] E. J. Pavlik, P. D. Depriest, H. H. Gallion et al., “Ovarian volume related to age,” Gynecologic Oncology, vol. 77, no. 3, pp. 410–412, 2000. [47] G. J. Scheﬀer, F. J. M. Broekmans, C. W. N. Looman et al., “The number of antral follicles in normal women with proven fertility is the best reﬂection of reproductive age,” Human Reproduction, vol. 18, no. 4, pp. 700–706, 2003. [48] C. Kaya, R. Pabuccu, and H. Satiroglu, “Serum antim u¨llerian hormone concentrations on day 3 of the in vitro stimulation cycle are predictive of the fertilisation, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction,” Fertility and Sterility, vol. 94, no. 6, pp. 2202–2207, 2010. [49] M. F. M. Mitwally, “Fertility preservation and minimizing reproductive damage in cancer survivors,” Expert Review of Anticancer Therapy, vol. 7, no. 7, pp. 989–1001, 2007.